Hazel Hunt Form 3 CORCEPT THERAPEUTICS / Hazel Hunt ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Hunt Hazel

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/13/2020

3. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	200	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	01/03/2021	Common Stock	50,000	3.96	D
Stock Option (Right to Buy)	(1)	08/09/2021	Common Stock	50,000	2.89	D
Stock Option (Right to Buy)	(1)	02/02/2022	Common Stock	40,000	3.32	D
Stock Option (Right to Buy)	(1)	01/30/2023	Common Stock	50,000	2.075	D
Stock Option (Right to Buy)	(1)	02/06/2024	Common Stock	100,000	3.02	D
Stock Option (Right to Buy)	(1)	09/11/2024	Common Stock	60,000	2.81	D
Stock Option (Right to Buy)	(1)	02/18/2025	Common Stock	150,000	3.29	D
Stock Option (Right to Buy)	(1)	02/26/2026	Common Stock	150,000	3.88	D
Stock Option (Right to Buy)	(2)	02/10/2027	Common Stock	200,000	8.27	D
Stock Option (Right to Buy)	(3)	02/07/2028	Common Stock	150,000	16.52	D
Stock Option (Right to Buy)	(4)	02/08/2029	Common Stock	150,000	11.35	D
Stock Option (Right to Buy)	(5)	02/07/2030	Common Stock	200,000	13.56	D

Explanation of Responses:

1. Fully exercisable.

2. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2021.

3. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2018, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2022.

4. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 8, 2019, so that the total number of shares subject to this option becomes fully vested and exercisable on February 8, 2023.

5. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2020, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2024.

Remarks:

	/s/ Joseph Douglas Lyon, Attorney-in-Fact for Hazel Hunt	07/15/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.